This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the�
- Investigators
- Carla Zingariello, S Parrish Winesett
- Status
- Accepting Candidates
- Ages
- 12 Years - 60 Years
- Sexes
- All